

FREEDOM OF INFORMATION REQUEST

RF23-400

Request:

1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:
 - Belantamab Mafodotin [Blenrep]
 - Bortezomib [Velcade] monotherapy or with dexamethasone
 - Bortezomib, thalidomide and dexamethasone [VTD]
 - Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
 - Carfilzomib [Kyprolis] and dexamethasone
 - Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone
 - Daratumumab [Darzalex] monotherapy
 - Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
 - Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
 - Elranatamab
 - Idecabtagene vicleucef [Abecma]
 - Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
 - Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)
 - Lenalidomide [Revlimid] monotherapy
 - Lenalidomide [Revlimid] and dexamethasone
 - Pomalidomide [Imnovid] and dexamethasone
 - Selinexor and dexamethasone
 - Talquetamab
 - Teclistamab [Tecvayli]
 - Any other systemic anti-cancer therapy

Response:

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.

1. 160
- 2.

Belantamab Mafodotin [Blenrep]	0
Bortezomib [Velcade] monotherapy or with dexamethasone	<5*
Bortezomib, thalidomide and dexamethasone [VTD]	<5*



Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)	5
Carfilzomib [Kyprolis] and dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone	<5*
Daratumumab [Darzalex] monotherapy	23
Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)	12
Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)	21
Elranatamab	0
Idecabtagene vicleucel [Abecma]	0
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)	5
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)	16
Lenalidomide [Revlimid] monotherapy	16
Lenalidomide [Revlimid] and dexamethasone	38
Pomalidomide [Imnovid] and dexamethasone	0
Selinexor and dexamethasone	0
Talquetamab	0
Teclistamab [Tecvayli]	0
Any other systemic anti-cancer therapy	19

* EKHUFT is unable to confirm the exact number where fewer than five patients are recorded. Given the low number, we consider that disclosure of such information, which constitutes personal data, would contravene the first data protection principle under GDPR. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle, which in our view, would be breached by disclosure. We believe that not disclosing this information is in line with Sections 40(2) and 40(3) of the Freedom of Information Act 2000.

(DATE OF RESPONSE: 05 JULY 2023)

